Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 105 of 6351
-
Gene therapy breakthrough? new trial targets hemophilia b patients previously excluded
Disease control Recruiting nowThe purpose of this study is to assess the risk of bleeding due to failure of expected pharmacological action of CSL222 in adults with severe or moderately severe hemophilia B with detectable pretreatment AAV5 Nabs.
Phase 3 • Sponsor: CSL Behring • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
New hope for advanced breast cancer: DB-1303 takes on T-DM1 in major trial
Disease control OngoingThis study is designed to compare efficacy and safety of DB-1303/BNT323 versus T-DM1 in HER2-positive, unresectable and/or metastatic breast cancer patients previously treated with trastuzumab and taxane.
Phase 3 • Sponsor: DualityBio Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Immunotherapy-Chemo combo aims to outperform standard chemoradiation in esophageal cancer
Disease control Recruiting nowThis is a multicenter, open-label, randomized, controlled clinical study to compare the efficacy and safety of cardonilizumab combined with neoadjuvant chemotherapy and surgery versus neoadjuvant chemoradiotherapy and surgery in locally advanced ESCC. Subjects were randomly divid…
Phase 2 • Sponsor: Tongji Hospital • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Sound waves open brain barrier to attack deadly tumor
Disease control Recruiting nowThe brain is protected from any toxic or inflammatory molecule by the blood-brain barrier (BBB). This physical barrier is located at the level of the blood vessel walls. Because of these barrier properties, the blood vessels are also impermeable to the passage of therapeutic mole…
Phase 3 • Sponsor: CarThera • Aim: Disease control
Last updated Sep 09, 2026 15:00 UTC
-
New hope for stomach cancer: targeted combo therapy enters final trial phase
Disease control OngoingThis study is a multicenter, randomized, double-blind, standard-of-care controlled phase III clinical study conducted in China. The purpose of this study is to evaluate the efficacy of ASKB589 plus CAPOX and PD-1 inhibitor compared with placebo plus CAPOX and PD-1 inhibitor (as f…
Phase 3 • Sponsor: AskGene Pharma, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New Clot-Buster shows promise for Tough-to-Treat strokes
Disease control CompletedThe trial is a multicentre, prospective, open-label, blinded endpoint (PROBE), phase 3, randomized controlled design. Patients with acute ischemic stroke due to basilar artery occlusion presenting within 24 hours will be randomized 1:1 to intravenous tenecteplase (0.25mg/kg, maxi…
Phase 3 • Sponsor: Beijing Tiantan Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New eye drug aims to save sight in wet AMD
Disease control CompletedMulticenter, randomized, masked, controlled study of the safety and effectiveness of intravitreally administered ONS-5010.
Phase 3 • Sponsor: Outlook Therapeutics, Inc. • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Promising new combo therapies aim to control multiple myeloma
Disease control OngoingThe purpose of this study is to compare the effectiveness of either talquetamab plus pomalidomide (Tal-P) or talquetamab plus teclistamab (Tal-Tec) with elotuzumab, pomalidomide, and dexamethasone (EPd) or pomalidomide, bortezomib, and dexamethasone (PVd).
Phase 3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Sound waves open brain barrier to attack deadly tumor
Disease control Recruiting nowBrain tumor treatment is hampered by the blood-brain barrier (BBB). This barrier prevents drugs carried in the bloodstream from getting into the brain. If the BBB can be opened, making it temporarily more permeable, drugs may able to better reach the brain tumor. In this trial we…
Phase 2 • Sponsor: Northwestern University • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New hope for hard-to-treat breast cancer: targeted drug takes on chemo in major trial
Disease control OngoingThe goal of this clinical trial is to assess the efficacy of DB-1303/BNT323 compared with investigator's choice chemotherapy in terms of progression-free survival (PFS) by blinded independent central review (BICR) in the HR+, HER2-low (immunohistochemistry \[IHC\]2+/in situ hybri…
Phase 3 • Sponsor: DualityBio Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
One-Time gene therapy aims to halt rare muscle disease
Disease control OngoingThis is a multicenter, global study of the effects of a single systemic dose of SRP-9003 on beta-sarcoglycan (β-SG) gene expression in participants with limb-girdle muscular dystrophy, type 2E/R4 (LGMD2E/R4). This study will consist of both ambulatory participants (Cohort 1) and …
Phase 3 • Sponsor: Sarepta Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New antibody aims to strip away Heart-Clogging protein in fatal heart disease
Disease control OngoingThe primary objective of this study is to access the efficacy of ALXN2220 in the treatment of adult participants with ATTR-CM by evaluating the difference between the ALXN2220 and placebo groups as assessed by the total occurrences of all-cause mortality (ACM) and cardiovascular …
Phase 3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Shorter hepatitis c treatment may be just as effective
Cure CompletedThis randomized controlled trial proposes to compare the treatment outcomes of 12 weeks versus 24 weeks of direct-acting antiviral (DAA) therapy in patients with HCV-related chronic liver disease, addressing the ongoing debate over the ideal treatment duration. To be conducted at…
Sponsor: Indus Hospital and Health Network • Aim: Cure
Last updated Jul 16, 2026 00:00 UTC
-
Can a pill combo outpace chemotherapy for aggressive breast cancer?
Disease control CompletedThis phase II study focuses on women with rapidly progressive hormone receptor-positive and HER2-negative advanced breast cancer, including patients with symptomatic visceral metastases, rapidly increasing tumor burden, impending organ dysfunction, or highly symptomatic non-visce…
Phase 2 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Could TB treatment be cut from 6 months to 8 weeks? major trial launches
Disease control Recruiting nowThe UNITE4TB consortium is a group of universities and pharmaceutical companies funded by the European Union. This consortium are carrying out a trial to find better and faster ways to treat tuberculosis (TB). The standard treatment for TB takes 24 weeks and uses four drugs. The …
Phase 2 • Sponsor: University College, London • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Mind-Controlled tech: Neuralink's brain implant trial begins
Disease control Recruiting nowThe PRIME Study is a first-in-human early feasibility study to evaluate the initial clinical safety and device functionality of the Neuralink N1 Implant and R1 Robot device designs in participants with tetraparesis or tetraplegia. The N1 Implant is a skull-mounted, wireless, rech…
Sponsor: Neuralink Corp • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Can a smart drug cross the Blood-Brain barrier to attack breast cancer metastases?
Disease control Recruiting nowThe purpose of this study is to test the safety and effectiveness of the study drug datopotamab deruxtecan in participants with metastatic breast cancer that has spread to the brain. The name of the study drug used in this research study is: Datopotamab deruxtecan (a type of an…
Phase 2 • Sponsor: Nancy Lin, MD • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Promising new combo targets Hard-to-Treat infant leukemia
Disease control OngoingThis phase II trial tests the safety and best dose of revumenib in combination with chemotherapy, and evaluates whether this treatment improves the outcome in infants and young children who have leukemia that has come back (relapsed) or does not respond to treatment (refractory) …
Phase 2 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Lab-Grown immune cells take aim at Life-Threatening viruses in vulnerable patients
Disease control By invitation onlyThe primary purpose of this phase I/II study is to evaluate whether partially matched, ≥1/6 Human Leukocyte Antigens (HLA) -matched, viral specific T cells have efficacy against adenovirus, Cytomegalovirus (CMV), and Epstein Barr Virus (EBV) in subjects who have previously receiv…
Phase 1/2 • Sponsor: Paul Szabolcs • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Experimental drug ION717 aims to slow fatal brain disease
Disease control OngoingThe purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of intrathecal (IT) delivery of ION717.
Phase 1/2 • Sponsor: Ionis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC